A Safety, Tolerability and Pharmacokinetic Study of Single and Multiple Doses of LY3526318 in Healthy Participants
Latest Information Update: 14 Jun 2021
At a glance
- Drugs LY 3526318 (Primary)
- Indications Pain
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
Most Recent Events
- 09 Jun 2021 Status changed from recruiting to completed.
- 20 Jan 2021 Status changed from not yet recruiting to recruiting.
- 29 Dec 2020 New trial record